EDGNEX Data Centers by DAMAC Announces Expansion into the U.S. Market with 2000MW projected future capacity

EDGNEX Data Centers by DAMAC Announces Expansion into the U.S. Market with 2000MW projected future capacity

EDGNEX announced an initial $20 Billion investment with a plan to potentially double the investment based on future demand The U.S. market is critical to EDGNEX's global and exponential growth strategy. As a group, DAMAC is invested significantly in...

Consumer Technology Association Announces New Global Innovation Champions

Consumer Technology Association Announces New Global Innovation Champions

Global Innovation Scorecard highlights countries that excel in broadband, autonomous vehicles, blockchain and more LAS VEGAS, Jan. 8, 2025 /PRNewswire/ -- Today at CES® 2025, the Consumer Technology Association (CTA)® announces the 2025 Global...

NAREIG Facilitates Landmark Transactions: $112 Million Beverly Hills Mansion and 300-Acre Vineyard in Sonoma

NAREIG Facilitates Landmark Transactions: $112 Million Beverly Hills Mansion and 300-Acre Vineyard in Sonoma

BEVERLY HILLS, Calif., Jan. 8, 2025 /PRNewswire/ -- NAREIG, a leading real estate agency specializing in connecting high-net-worth Chinese investors with premier U.S. real estate opportunities, proudly announces its role in facilitating two landmark...

MedicosBiotech Wins CES 2025 Innovation Award in Digital Health

MedicosBiotech Wins CES 2025 Innovation Award in Digital Health

SEOUL, South Korea, Jan. 8, 2025 /PRNewswire/ -- MedicosBiotech proudly announces its recognition at CES 2025, the world's premier technology event, as a recipient of the prestigious CES Innovation Award in the Digital Health category. This award...

Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease

Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease

Two separate Phase I studies conducted in Australia and in China indicate that ISM5411 was generally safe and well tolerated in all dose groups, demonstrating a favorable PK profile in validating gut-restrictive properties. Supported by Insilico's...

Massimo Motor Expands Nationwide Reach with 6th Distribution Center in Illinois

Massimo Motor Expands Nationwide Reach with 6th Distribution Center in Illinois

Midwest hub to support Massimo's robust network of partners and customers in the region GARLAND, Texas, Jan. 7, 2025 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO) ("Massimo"), a manufacturer and distributor of powersports vehicles and pontoon boats,...

Moomoo Announces Global Partnership With Seeking Alpha to Amplify Trading Potential for Investors

Moomoo Announces Global Partnership With Seeking Alpha to Amplify Trading Potential for Investors

JERSEY CITY, N.J., Jan. 7, 2025 /PRNewswire/ -- Moomoo, one of the world's leading investment and trading platforms, today announced its partnership with Seeking Alpha, a leading financial research platform powered by one of the world's largest...

Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma

Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma

Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI). The partnership with IFLI will accelerate the clinical development of SynKIR™-310 in Follicular Lymphoma (FL) by leveraging...

Segway Officially Recognized as Global No.1 Brand in eKickScooter Sales

Segway Officially Recognized as Global No.1 Brand in eKickScooter Sales

Micromobility leader announces verified milestone as it debuts new models during CES 2025 LAS VEGAS, Jan. 7, 2025 /PRNewswire/ -- Segway, the global leader in micromobility transportation solutions, has been recognized as the "global No.1 brand of...

GORTEC Announces New Trial Success for Head and Neck Cancer Treatment

GORTEC Announces New Trial Success for Head and Neck Cancer Treatment

TOURS, France, Jan. 7, 2025 /PRNewswire/ -- GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as a...

  • 1
  • ...
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • ...
  • 48
  • menu
    menu